GEN Exclusives

More »

GEN News Highlights

More »
Aug 2, 2010

Almac to Help Clients Develop Biomarker Strategies for Drug Candidates

Almac to Help Clients Develop Biomarker Strategies for Drug Candidates

Biomarkers for biopharma will offer range of biomarker services and tools.

  • Drug development services firm Almac launched its biomarkers for biopharma services to help clients establish biomarker strategies as part of their drug development process. The new initiative combines pharmacodynamic solutions, patient selection markers, assay development, and bioinformatics/biostatistics consultancy services. The services will exploit Almac’s existing expertise in the biomarker discovery field, including its Xcel™ array platform for biomarker discovery, which it launched in June.

    Almac comprises five integrated divisions offering services spanning R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and technology, and commercial-scale manufacture. The firm's expertise in biomarkers is being commercialized through partnerships for the development of companion diagnostics, pharmacodynamic biomarkers, prognostic tests, and drug repositioning. 

    In June Almac teamed up with Aeterna Zentaris in a collaboration that aims to develop a companion diagnostic for the latter’s doxorubicin luteinizing hormone-releasing hormone targeted conjugate compound, AEZS-108. During April Almac announced a partnership with Merck KGaA and the U.K.’s Medical Research Council to investigate the development of biomarkers of response to Erbitux®

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »